GlassScriptPhysician profile
Jasmin Chaudhary
NPI 1558596916
$4,156.31
in general payments reported to CMS, 2019-2025
32 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $197 · 2021: $193 · 2022: $103 · 2023: $676 · 2024: $1,378 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,092 · Education: $83.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.38 |
| Education | $83.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $645.61 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $644.01 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $513.83 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Insmed, INC. | $415.89 | 2022-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $319.63 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Amgen INC. | $259.33 | 2019-2024 | Prolia, Evenity, Krystexxa |
| Aimmune Therapeutics, INC. | $162.96 | 2024 | |
| Astellas Pharma US INC | $154.57 | 2023-2025 | Cresemba |
| Comsort, INC | $150.00 | 2019 | |
| Pfizer INC. | $135.54 | 2023-2025 | |
| Melinta Therapeutics, LLC | $90.89 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Tetraphase Pharmaceuticals, INC. | $76.02 | 2020 | |
| Shionogi INC | $67.95 | 2022-2025 | Fetroja |
| Allergan, INC. | $54.63 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $52.84 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $44.97 | 2021 | |
| Ferring Pharmaceuticals INC. | $44.87 | 2024 | Rebyota |
| Octapharma USA, INC. | $38.49 | 2023 | Panzyga |
| Alexion Pharmaceuticals, INC. | $31.45 | 2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $31.08 | 2023 | |
| Pharming Healthcare, INC. | $29.78 | 2023-2024 | Ruconest |
| Novartis Pharmaceuticals Corporation | $26.33 | 2025 | |
| Daiichi Sankyo INC. | $22.00 | 2025 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $19.60 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.84 | 2023 | Ofev |
| Kyowa Kirin, INC. | $18.84 | 2023 | Crysvita |
| La Jolla Pharmaceutical Company | $15.59 | 2020 | |
| Celgene Corporation | $15.29 | 2024 | Orencia |
| Ucb, INC. | $14.66 | 2025 | Bimzelx |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2021 | |
| Biocon Biologics INC | $13.81 | 2025 | Hulio |
| Janssen Biotech, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmin Chaudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.